Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis.
Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis.
复制标题
DOI：
10.1039/c5nr08423g
复制
发表时间：
2016-02
期刊：
影响因子：
6.7
通讯作者：
Nathan J Liu;R. Chapman;Yiyang Lin;Jonas Mmesi;A. Bentham;M. Tyreman;S. Abraham;M. Stevens
中科院分区：
文献类型：
--
作者：
Nathan J Liu;R. Chapman;Yiyang Lin;Jonas Mmesi;A. Bentham;M. Tyreman;S. Abraham;M. Stevens
Secretory phospholipase A2 group IIA (sPLA2-IIA) was examined as a point of care marker for determining disease activity in rheumatoid (RA) and psoriatic (PsA) arthritis. Serum concentration and activity of sPLA2-IIA were measured using in-house antibodies and a novel point of care lateral flow device assay in patients diagnosed with varying severities of RA (n = 30) and PsA (n = 25) and found to correlate strongly with C-reactive protein (CRP). Levels of all markers were elevated in patients with active RA over those with inactive RA as well as both active and inactive PsA, indicating that sPLA2-IIA can be used as an analogue to CRP for RA diagnosis at point of care.
